ALD-话题@MedSci

#ALD#

59篇内容 | 2179人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1469398, encodeId=2cc8146939812, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Lancet Gastroen Hepatol：Naldemedine缓解阿片类药物引起的便秘, objectType=article, longId=106614, objectId=cdaa10661470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdaa10661470, replyNumber=0, likeNumber=75, createdTime=2017-07-27, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdaa10661470, moduleTitle=Lancet Gastroen Hepatol：Naldemedine缓解阿片类药物引起的便秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdaa10661470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469397, encodeId=a0cb146939e04, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Blood：基因疗法对Wiskott-Aldrich综合征重度患者的疗效。, objectType=article, longId=105873, objectId=3cbf1058e3bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cbf1058e3bf, replyNumber=0, likeNumber=67, createdTime=2017-07-20, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cbf1058e3bf, moduleTitle=Blood：基因疗法对Wiskott-Aldrich综合征重度患者的疗效。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cbf1058e3bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469396, encodeId=af441469396f8, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Redox Biol：ALDH2缺乏患者不应使用ALDHbr细胞治疗外周缺血性疾病！, objectType=article, longId=103806, objectId=192410380680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192410380680, replyNumber=0, likeNumber=72, createdTime=2017-06-30, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192410380680, moduleTitle=Redox Biol：ALDH2缺乏患者不应使用ALDHbr细胞治疗外周缺血性疾病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=192410380680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469395, encodeId=324b14693955a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Nat Commun：VHL缺陷通过下调ALDH2增强透明细胞肾细胞癌的蒽环霉素敏感性, objectType=article, longId=102127, objectId=012a10212ec3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=012a10212ec3, replyNumber=0, likeNumber=68, createdTime=2017-06-17, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=012a10212ec3, moduleTitle=Nat Commun：VHL缺陷通过下调ALDH2增强透明细胞肾细胞癌的蒽环霉素敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=012a10212ec3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469394, encodeId=5c5614693942e, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=JCO：Naldemedine对癌症伴腹泻患者的疗效研究, objectType=article, longId=97415, objectId=cc999e415fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc999e415fe, replyNumber=0, likeNumber=79, createdTime=2017-04-29, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc999e415fe, moduleTitle=JCO：Naldemedine对癌症伴腹泻患者的疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc999e415fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469393, encodeId=0d3b14693931b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Alder公司授权Vitaeris开发IL-6新药, objectType=article, longId=68076, objectId=fdfc680e617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfc680e617, replyNumber=0, likeNumber=65, createdTime=2016-05-14, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfc680e617, moduleTitle=Alder公司授权Vitaeris开发IL-6新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfc680e617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469392, encodeId=a6ae1469392be, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=纪念伟大的免疫学家：Donald Metcalf, objectType=article, longId=46437, objectId=7d3f4643eef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d3f4643eef, replyNumber=0, likeNumber=52, createdTime=2015-02-01, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d3f4643eef, moduleTitle=纪念伟大的免疫学家：Donald Metcalf, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d3f4643eef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469391, encodeId=07e414693914f, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=不再高不可攀，Abbvie新药或将撼动吉利德Sovaldi霸主地位, objectType=article, longId=43096, objectId=60a043096fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60a043096fb, replyNumber=0, likeNumber=73, createdTime=2014-11-27, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60a043096fb, moduleTitle=不再高不可攀，Abbvie新药或将撼动吉利德Sovaldi霸主地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60a043096fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469390, encodeId=01d1146939010, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=昙花一现：Olysio被FDA批准和Sovaldi联用用于一型丙肝的治疗, objectType=article, longId=42365, objectId=d14b423651d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d14b423651d, replyNumber=0, likeNumber=74, createdTime=2014-11-12, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d14b423651d, moduleTitle=昙花一现：Olysio被FDA批准和Sovaldi联用用于一型丙肝的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d14b423651d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469389, encodeId=0e1f14693892e, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=医药界诺奖揭晓：丙肝明星药Sovaldi获更佳药品奖, objectType=article, longId=42018, objectId=c562420185d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c562420185d, replyNumber=0, likeNumber=80, createdTime=2014-11-02, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c562420185d, moduleTitle=医药界诺奖揭晓：丙肝明星药Sovaldi获更佳药品奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c562420185d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469388, encodeId=d1041469388d9, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Achillion丙肝药物ACH-3102二期临床数据良好有望挑战Sovaldi, objectType=article, longId=39211, objectId=2b2b39211da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2b39211da, replyNumber=0, likeNumber=83, createdTime=2014-08-20, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2b39211da, moduleTitle=Achillion丙肝药物ACH-3102二期临床数据良好有望挑战Sovaldi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b2b39211da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469387, encodeId=bb1f146938e14, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=美国人民愤怒了——吉利德天价丙肝药Sovaldi印度售价仅1%, objectType=article, longId=38939, objectId=5fa5389396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fa5389396e, replyNumber=0, likeNumber=85, createdTime=2014-08-13, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fa5389396e, moduleTitle=美国人民愤怒了——吉利德天价丙肝药Sovaldi印度售价仅1%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fa5389396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469386, encodeId=6411146938638, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=Sovaldi对日本人丙肝实现100%治愈率（GS-US-337-0113研究）, objectType=article, longId=36897, objectId=e2173689e2d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2173689e2d, replyNumber=0, likeNumber=0, createdTime=2014-06-25, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2173689e2d, moduleTitle=Sovaldi对日本人丙肝实现100%治愈率（GS-US-337-0113研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2173689e2d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469385, encodeId=29f314693855a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=吉利德丙肝新药Sovaldi日本III期试验达主要终点, objectType=article, longId=33000, objectId=3fca33000a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fca33000a7, replyNumber=0, likeNumber=83, createdTime=2014-04-10, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fca33000a7, moduleTitle=吉利德丙肝新药Sovaldi日本III期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fca33000a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469384, encodeId=1775146938457, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=勃林格faldaprevir治疗HCV/HIV合并感染III期取得积极数据, objectType=article, longId=31630, objectId=b140316307c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b140316307c, replyNumber=0, likeNumber=0, createdTime=2014-03-09, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b140316307c, moduleTitle=勃林格faldaprevir治疗HCV/HIV合并感染III期取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b140316307c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469383, encodeId=48bf146938323, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=吉利德丙肝新药Sovaldi获欧盟批准, objectType=article, longId=29656, objectId=48722965625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48722965625, replyNumber=0, likeNumber=48, createdTime=2014-01-22, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48722965625, moduleTitle=吉利德丙肝新药Sovaldi获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48722965625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469382, encodeId=f3f114693826e, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=吉利德丙肝新药Sovaldi获FDA批准, objectType=article, longId=27830, objectId=0bb52e8303b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bb52e8303b, replyNumber=0, likeNumber=73, createdTime=2013-12-12, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bb52e8303b, moduleTitle=吉利德丙肝新药Sovaldi获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bb52e8303b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469381, encodeId=632d146938128, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=BI旗下HCV新药 Faldaprevir获欧洲加速审评资格, objectType=article, longId=27440, objectId=70d62e4402f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70d62e4402f, replyNumber=0, likeNumber=66, createdTime=2013-12-04, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70d62e4402f, moduleTitle=BI旗下HCV新药 Faldaprevir获欧洲加速审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70d62e4402f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469380, encodeId=c9c4146938096, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=EMA授予勃林格丙肝药物faldaprevir加速评估, objectType=article, longId=27222, objectId=c0e12e22280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e12e22280, replyNumber=0, likeNumber=63, createdTime=2013-11-29, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e12e22280, moduleTitle=EMA授予勃林格丙肝药物faldaprevir加速评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e12e22280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1469379, encodeId=1b7114693e932, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, objectTitle=ESC 2013：Eugene Braunwald教授总结心脏病学领域十大历史事件, objectType=article, longId=23747, objectId=c5bd23e47be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5bd23e47be, replyNumber=0, likeNumber=73, createdTime=2013-09-05, rootId=0, userName=zhangjingnwpu, userId=64f67025397, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5bd23e47be, moduleTitle=ESC 2013：Eugene Braunwald教授总结心脏病学领域十大历史事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5bd23e47be)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALD

2020-05-29

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Lancet Gastroen Hepatol：Naldemedine缓解阿片类药物引起的便秘

2017-07-27

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Blood：基因疗法对Wiskott-Aldrich综合征重度患者的疗效。

2017-07-20

智者为医08 (审核中...)

前往app查看评论内容

#ALD#

Redox Biol：ALDH2缺乏患者不应使用ALDHbr细胞治疗外周缺血性疾病！

2017-06-30

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Nat Commun：VHL缺陷通过下调ALDH2增强透明细胞肾细胞癌的蒽环霉素敏感性

2017-06-17

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

JCO：Naldemedine对癌症伴腹泻患者的疗效研究

2017-04-29

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Alder公司授权Vitaeris开发IL-6新药

2016-05-14

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

纪念伟大的免疫学家：Donald Metcalf

2015-02-01

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

不再高不可攀，Abbvie新药或将撼动吉利德Sovaldi霸主地位

2014-11-27

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

昙花一现：Olysio被FDA批准和Sovaldi联用用于一型丙肝的治疗

2014-11-12

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

医药界诺奖揭晓：丙肝明星药Sovaldi获更佳药品奖

2014-11-02

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Achillion丙肝药物ACH-3102二期临床数据良好有望挑战Sovaldi

2014-08-20

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

美国人民愤怒了——吉利德天价丙肝药Sovaldi印度售价仅1%

2014-08-13

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

Sovaldi对日本人丙肝实现100%治愈率（GS-US-337-0113研究）

2014-06-25

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

吉利德丙肝新药Sovaldi日本III期试验达主要终点

2014-04-10

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

勃林格faldaprevir治疗HCV/HIV合并感染III期取得积极数据

2014-03-09

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

吉利德丙肝新药Sovaldi获欧盟批准

2014-01-22

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

吉利德丙肝新药Sovaldi获FDA批准

2013-12-12

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

BI旗下HCV新药 Faldaprevir获欧洲加速审评资格

2013-12-04

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

EMA授予勃林格丙肝药物faldaprevir加速评估

2013-11-29

zhangjingnwpu (审核中...)

前往app查看评论内容

#ALD#

ESC 2013：Eugene Braunwald教授总结心脏病学领域十大历史事件

2013-09-05

科室
- - 订阅+
  - 更多科室
工具
服务